Walleye Trading’s Coherus Oncology CHRS Stock Holding History

Walleye Trading’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-14,500	Closed	-$357K	–	4712
2016 Q4	$408K	Buy	+14,500	New	+$406K	﹤0.01%	2244

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Walleye Trading's CHRS Position: Q1 2017 in Review

Walleye Trading sold out of Coherus Oncology (CHRS) in Q1 2017, closing a stake of 14,500 shares — an estimated $357K sold.

Walleye Trading first reported a position in CHRS in Q4 2016 and held it in 1 quarter. The position peaked at $408K in Q4 2016. 109 funds tracked by Wall St. Rank hold CHRS as of Q1 2017.

Walleye Trading reported no remaining Coherus Oncology position as of Q1 2017 after selling out during the quarter.
Walleye Trading sold 14,500 Coherus Oncology shares in Q1 2017, an estimated $357K.
Walleye Trading first reported a position in Coherus Oncology in Q4 2016 and held it in 1 quarter.
Walleye Trading's Coherus Oncology position peaked at $408K in Q4 2016.
109 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2017.

Based on Walleye Trading's 13F filing for Q1 2017, filed 15 May 2017.